Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2024-11-25 Share Issue/Capital Cha…
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - PER 5 pages 16.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form titled 'Application for quotation of securities' from Percheron Therapeutics Limited. It details the application to list newly issued securities on the ASX, referencing a previous Appendix 3B announcement about the securities issue. The document is a formal announcement related to capital market activities, specifically the quotation of securities following a prior placement. It does not contain financial statements, management discussion, or audit information. It is not a report but an official announcement related to capital structure changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is 4537 characters, which is consistent with an announcement rather than a full report.
2024-11-25 English
Notification regarding unquoted securities - PER 6 pages 20.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted options by Percheron Therapeutics Limited. It includes specifics such as the number of securities issued, issue dates, and references to previous announcements (Appendix 3B). The content focuses on the notification of securities issuance rather than a full financial report or earnings release. This type of document corresponds to announcements about share issues or capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a brief announcement of a report but a substantive notification of capital changes.
2024-11-24 English
Change of Director's Interest Notice Dr James Garner 3 pages 223.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y' and is a 'Change of Director's Interest Notice' filed under ASX listing rule 3.19A.2. It details the change in securities holdings of a company director, including the number of shares and options acquired, disposed, and held before and after the change. The document references the Corporations Act and ASX rules, indicating it is a regulatory filing related to insider trading disclosures by directors. There is no financial report, earnings data, or management discussion present. The content fits the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is 8294 characters, sufficient to contain detailed information. Therefore, the correct classification is DIRS (Director's Dealing).
2024-11-24 English
Change of Director's Interest Notice - Dr Ben Gil Price 3 pages 223.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and options held before and after the change, the nature of the change, and dates. This is a clear report of personal share transactions by a company director. The document is not an announcement of a report, nor does it contain financial statements or management discussion. It fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades).
2024-11-24 English
Withdrawal of Resolutions from the Annual General Meeting 1
AGM Information Classification · 95% confidence The document is an ASX announcement regarding the withdrawal of certain resolutions from the company's upcoming Annual General Meeting (AGM). It discusses procedural matters related to the AGM but does not contain the AGM materials themselves, nor does it provide financial data or results. The document is short (2566 characters) and serves as a notice about changes to the AGM agenda. Therefore, it is best classified as an AGM Information announcement (AGM-R).
2024-11-20 English
Annual General Meeting - Chair's Address 5 pages 177.1KB
AGM Information Classification · 100% confidence The document is an ASX announcement containing the Chair's address to the Annual General Meeting (AGM) of Percheron Therapeutics Limited held on 21 November 2024. It includes a detailed speech reviewing the company's progress, clinical trial updates, capital raising, and acknowledgments to shareholders and management. The content is clearly the presentation material shared at the AGM, not a report or announcement of voting results. The document length is 9481 characters, which is substantial and contains the full text of the Chair's address. Therefore, this fits the definition of AGM Information (AGM-R).
2024-11-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.